The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...
Verywell Health on MSN1mon
Understanding AVNRT (Atrioventricular Nodal Reentrant Tachycardia)Atrioventricular nodal reentrant tachycardia (AVNRT) is a rapid, irregular heartbeat that starts suddenly and without warning ...
CRL focused on CMC; no clinical issues relating to etripamil raised$69.7M in cash, cash equivalents and short-term investments as of December 31, ...
TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone announced the FDA ...
Cardiovascular-focused Milestone Pharmaceuticals was trading more than 60% lower early in trading on Friday, with its share ...
MONTREAL and CHARLOTTE, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced the U.S. Food and Drug Administration (FDA) issued a Complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback